Roche Diabetes Care’s Michael Goetzl explains how the company is spearheading a combined digital-pharmaceutical approach to diabetes and how pharma firms can best embrace holistic strategie
Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
John Grumitt, vice president of Diabetes UK and chief executive of Changing Health, says digital health innovators can work with big pharma to address medical needs.
